Pyxis Oncology, Inc. (PYXS)
Company Description
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers.
Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma.
The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer.
The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 1, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Dr. Lara S. Sullivan M.D., MBA |
Contact Details
Address: 321 Harrison Avenue Boston, Massachusetts 02118 United States | |
| Phone | (617) 221-9059 |
| Website | pyxisoncology.com |
Stock Details
| Ticker Symbol | PYXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001782223 |
| CUSIP Number | 747324101 |
| ISIN Number | US7473241013 |
| Employer ID | 83-1160910 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John L. Flavin M.B.A., MBA, Ph.D. | Co-Founder and Independent Chairman |
| Dr. Lara S. Sullivan M.D., MBA | Chief Executive Officer, President and Director |
| Pamela Yanchik Connealy M.B.A. | Chief Financial Officer |
| Dr. Jay M. Feingold M.D., Ph.D. | Chief Medical Officer |
| Jitendra Wadhane | Chief Accounting Officer, Senior Vice President of Finance and Corporate Controller |
| Dr. Balu N. Balasubramanian Ph.D. | Interim Chief Technology Officer |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Martina Molsbergen B.S. | Interim Chief Business Officer |
| Dr. Charles T. Gombar Ph.D. | Senior Vice President of Portfolio and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 28, 2023 | 8-K | Current Report |
| Nov 7, 2023 | 10-Q | Quarterly Report |
| Nov 7, 2023 | 8-K | Current Report |
| Oct 27, 2023 | 8-K/A | [Amend] Current report |
| Sep 18, 2023 | 144 | Filing |
| Sep 14, 2023 | 144 | Filing |
| Sep 13, 2023 | 144 | Filing |
| Sep 12, 2023 | 144 | Filing |
| Sep 11, 2023 | 144 | Filing |
| Sep 5, 2023 | 144 | Filing |